A new menin-MLL inhibitor (VTP-50469) appears to promote leukemia cell differentiation through direct effects on the HOX cofactor MEIS1 [HOX expression has been shown to be essential to maintain the leukemic phenotype of MLLr (50)]. This evidence concerns the gene KMT2A and leukemia.